Reversal agents for NOACs: Connecting the dots

Abstract Objective The objective of this review is to provide an overview on the current development of the specific reversal agents for Non-vitamin K Oral Anticoagulants (NOACs). Methods We conducted a systematic literature search strategy to identify potential studies on Medline, Embase, and the C...

Full description

Saved in:
Bibliographic Details
Published inIndian heart journal Vol. 68; no. 4; pp. 559 - 563
Main Authors Dalal, Jamshed, Bhave, Abhay, Chaudhry, Gaurav, Rana, Prashant
Format Journal Article
LanguageEnglish
Published India Elsevier B.V 01.07.2016
Elsevier
Subjects
Adexanet alfa
Administration, Oral
Anticoagulants - administration & dosage
Atrial Fibrillation - drug therapy
Cardiovascular
Humans
Idarucizumab
Intracranial Hemorrhages - prevention & control
NOACs
Recombinant Proteins - administration & dosage
Reversal agents
Review
SPAF
Vitamin K
NOACs
SPAF
NOAC
Vitamin K Antagonist
Prothrombin Complex Concentrate
Non vitamin K Oral Anticoagulant
Adexanet alfa
VKA
Reversal agents
ICH
PCC
IntraCranial Hemorrhage
Idarucizumab
Online AccessGet full text

Cover

More Information
Summary:Abstract Objective The objective of this review is to provide an overview on the current development of the specific reversal agents for Non-vitamin K Oral Anticoagulants (NOACs). Methods We conducted a systematic literature search strategy to identify potential studies on Medline, Embase, and the Cochrane register. Conclusions These new reversal agents for NOACs, will help address the unmet need for the management of major or life threatening bleeds, and the management of emergency surgical procedures in patients taking NOACs. It will increase confidence in the use of NOACs; thereby extending treatment to a wider range of patients.
ISSN:0019-4832
2213-3763
DOI:10.1016/j.ihj.2015.11.023